Should flupenthixol versus placebo be used for people who self-harm?

Quality assessmentNo. of patientsEffectQualityImportance
No. of studiesDesignLimitationsInconsistencyIndirectnessImprecisionOther considerationsFlupenthixolPlaceboRelative risk (95% CI)Absolute
Repetition – during 6 months after trial entry
1Randomised trialsNo serious limitations--Serious1None3/14 (21.4%)12/16 (75%)RR 0.29 (0.1 to 0.81)533 fewer per 1000 (from 142 fewer to 675 fewer)--
-75%533 fewer per 1000 (from 142 fewer to 675 fewer)
1Randomised trialsNo serious limitations---None14/18 (77.8%)16/19 (84.2%)Not pooledNot pooled--
-84.2%Not pooled

Total sample size is smaller than 300

From: Appendix 17, GRADE evidence profiles

Cover of Self-Harm: Longer-Term Management
Self-Harm: Longer-Term Management.
NICE Clinical Guidelines, No. 133.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2012.
Copyright © 2012, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.